Clinical Trial Update: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Tarlatamab in combination with YL201, with or without anti-PD-L1, in extensive-stage small cell lung cancer is active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab
• YL201

Snippet

Sponsor: Amgen | Conditions: Small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING